Lexaria grants exclusive global license to SulfoSyn for DehydraTECH-sulforaphane non-pharmaceutical products

Lexaria Bioscience Corp.

Up-front cash payment received; minimum future payments and ongoing royalties agreed.
Lexaria contracted for manufacturing at US partner facility for initial 2-year term.
DehydraTECH applied to sulforaphane, a compound with anti-inflammatory and antioxidant properties.
Non-pharmaceutical uses include supplements, additives, foods, and dietary ingredients.
SulfoSyn granted sub-licensing rights for the licensed technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.